肝癌术后早期复发预测列线图的建立与验证
Establishment and Validation of Nomogram for Predicting Early Postoperative Recurrence of Liver Cancer
DOI: 10.12677/acm.2024.143917, PDF,   
作者: 马永辉, 曹景玉*:青岛大学附属医院肝胆胰外科,山东 青岛
关键词: 肝细胞癌复发预测模型Hepatocellular Carcinoma Recurrence Prediction Model
摘要: 背景:对于肝细胞癌(HCC)患者而言,肝切除术后早期复发是治疗过程中面临的一项严峻挑战。本研究旨在开发并验证一个新型的模型,用以预测肝切除术后HCC患者的早期复发风险。患者与方法:本项研究回顾性分析了青岛大学附属医院在2013年1月至2021年12月期间,共459例接受根治性肝切除手术的HCC患者。所有参与者按照7:3的比例随机分为训练组(321例)和验证组(178例)。我们结合了多种影响早期复发的风险因素,利用患者的术前临床数据和术后病理特征,构建了一个用于预测肝细胞癌复发风险的列线图模型。结果:我们建立的logistic多因素模型的列线图在预测复发方面表现出较高的准确性,其一致性指标为0.78。经校正的预测曲线与实际预测结果之间展现出良好的一致性。结论:本研究开发的术后列线图模型能够有效预测HCC患者的早期复发率和生存率,这一模型不仅有助于提升治疗效果,同时也可作为临床医生指导肝细胞癌患者治疗决策的有价值工具。
Abstract: Background: Early recurrence after hepatectomy is a formidable challenge in the treatment of hepatocellular carcinoma (HCC) patients. This study aims to develop and validate a novel model for predicting the risk of early recurrence in HCC patients post-hepatectomy. Patients and Methods: This retrospective study analyzed a total of 459 HCC patients who underwent curative liver resection at the Affiliated Hospital of Qingdao University from January 2013 to December 2021. All participants were randomly divided into a training cohort (321 cases) and a validation cohort (178 cases) in a ratio of 7:3. We combined multiple risk factors influencing early recurrence to construct a nomogram model based on preoperative clinical data and postoperative pathological features to predict the recurrence risk of hepatocellular carcinoma. Results: The logistic multifactorial model’s nomogram we established demonstrated high accuracy in predicting recurrence, with a concordance index of 0.78. The calibrated prediction curve showed good consistency with the actual observed outcomes. Conclusion: The postoperative nomogram model developed in this study effectively predicts early recurrence and survival rates in HCC patients. This model not only helps to improve treatment outcomes but also serves as a valuable tool for clinical physicians in guiding treatment decisions for hepatocellular carcinoma patients.
文章引用:马永辉, 曹景玉. 肝癌术后早期复发预测列线图的建立与验证[J]. 临床医学进展, 2024, 14(3): 1859-1873. https://doi.org/10.12677/acm.2024.143917

参考文献

[1] Lee, S., Kang, T., Song, K., et al. (2021) Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma after Surgery and Radiofrequency Ablation. Annals of Surgery, 273, 564-571. [Google Scholar] [CrossRef
[2] Endo, Y., Alaimo, L., Lima, H., et al. (2023) A Novel Online Calculator to Predict Risk of Microvascular Invasion in the Preoperative Setting for Hepatocellular Carcinoma Patients Undergoing Curative-Intent Surgery. Annals of Surgical Oncology, 30, 725-733. [Google Scholar] [CrossRef] [PubMed]
[3] Kloeckner, R., Galle, P. and Bruix, J. (2021) Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology, 73, 137-149. [Google Scholar] [CrossRef] [PubMed]
[4] Xie, D.-Y., Ren, Z.-G., Fan, J., Gao, Q. and Zhou, J. (2020) 2019 Chinese Clinical Guidelines for the Management of Hepatocellular Carcinoma: Updates and Insights. HepatoBiliary Surgery and Nutrition, 9, 452-463. [Google Scholar] [CrossRef] [PubMed]
[5] Portolani, N., Coniglio, A., Ghidoni, S., et al. (2006) Early and Late Recurrence after Liver Resection for Hepatocellular Carcinoma: Prognostic and Therapeutic Implications. Annals of Surgery, 243, 229-235. [Google Scholar] [CrossRef] [PubMed]
[6] Yamamoto, Y., Ikoma, H., Morimura, R., et al. (2015) Optimal Duration of the Early and Late Recurrence of Hepatocellular Carcinoma after Hepatectomy. World Journal of Gastroenterology, 21, 1207-1215. [Google Scholar] [CrossRef] [PubMed]
[7] Tabrizian, P., Jibara, G., Shrager, B., et al. (2015) Recurrence of Hepatocellular Cancer after Resection: Patterns, Treatments, and Prognosis. Annals of Surgery, 261, 947-955. [Google Scholar] [CrossRef
[8] Villanueva, A. (2019) Hepatocellular Carcinoma. The New England Journal of Medicine, 380, 1450-1462. [Google Scholar] [CrossRef
[9] Chan, A.W.H., Zhong, J.H., Berhane, S., et al. (2018) Development of Pre and Post-Operative Models to Predict Early Recurrence of Hepatocellular Carcinoma after Surgical Resection. Journal of Hepatology, 69, 1284-1293. [Google Scholar] [CrossRef] [PubMed]
[10] Fu, X., Yang, Y. and Zhang, D. (2022) Molecular Mechanism of Albumin in Suppressing Invasion and Metastasis of Hepatocellular Carcinoma. Liver International, 42, 696-709. [Google Scholar] [CrossRef] [PubMed]
[11] Fattovich, G., Stroffolini, T., Donato, F. and Zagni, I. (2004) Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors. Gastroenterology, 127, S35-S50. [Google Scholar] [CrossRef] [PubMed]
[12] Moon, A.M., Singal, A.G. and Tapper, E.B. (2020) Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clinical Gastroenterology and Hepatology, 18, 2650-2666. [Google Scholar] [CrossRef] [PubMed]
[13] Mazzaferro, V., Llovet, J., Miceli, R., et al. (2009) Predicting Survival after Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Retrospective, Exploratory Analysis. The Lancet Oncology, 10, 35-43. [Google Scholar] [CrossRef
[14] Pawlik, T.M., Delman, K.A., Vauthey, J.-N., et al. (2005) Tumor Size Predicts Vascular Invasion and Histologic Grade: Implications for Selection Of Surgical Treatment for Hepatocellular Carcinoma. Liver Transplantation, 11, 1086-1092. [Google Scholar] [CrossRef] [PubMed]
[15] Onaca, N., Davis, G.L., Jennings, L.W., et al. (2009) Improved Results of Transplantation for Hepatocellular Carcinoma: A Report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transplantation, 15, 574-580. [Google Scholar] [CrossRef] [PubMed]
[16] Sheng, X., Ji, Y., Ren, G.-P., Lu, C.-L., Yun, J.-P., Chen, L.-H., et al. (2020) A Standardized Pathological Proposal for Evaluating Microvascular Invasion of Hepatocellular Carcinoma: A Multicenter Study by LCPGC. Hepatology International, 14, 1034-1047. [Google Scholar] [CrossRef] [PubMed]
[17] Isik, B., Gonultas, F., Sahin, T. and Yilmaz, S. (2020) Microvascular Venous Invasion in Hepatocellular Carcinoma: Why Do Recurrences Occur? Journal of Gastrointestinal Cancer, 51, 1133-1136. [Google Scholar] [CrossRef] [PubMed]
[18] Wickham, S., West, M.B., Cook, P.F. and Hanigan, M.H. (2011) Gamma-Glutamyl Compounds: Substrate Specificity of Gamma-Glutamyl Transpeptidase Enzymes. Analytical Biochemistry, 414, 208-214. [Google Scholar] [CrossRef] [PubMed]
[19] Bachhawat, A.K. and Kaur, A. (2017) Glutathione Degradation. Antioxidants & Redox Signaling, 27, 1200-1216. [Google Scholar] [CrossRef] [PubMed]
[20] Bai, C., Zhang, M., Zhang, Y., He, Y., Dou, H., Wang, Z., et al. (2022) Gamma-Glutamyltransferase Activity (GGT) Is a Long-Sought Biomarker of Redox Status in Blood Circulation: A Retrospective Clinical Study of 44 Types of Human Diseases. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 8494076. [Google Scholar] [CrossRef] [PubMed]
[21] Corti, A., Belcastro, E., Dominici, S., Maellaro, E. and Pompella, A. (2020) The Dark Side of Gamma-Glutamyltransferase (GGT): Pathogenic Effects of an ‘Antioxidant’ Enzyme. Free Radical Biology & Medicine, 160, 807-819. [Google Scholar] [CrossRef] [PubMed]
[22] Wong, L., Bozhilov, K., Hernandez, B., Kwee, S., Chan, O., Ellis, L., et al. (2019) Underlying Liver Disease and Advanced Stage Liver Cancer Are Associated with Elevated Neutrophil-Lymphocyte Ratio. Clinical and Molecular Hepatology, 25, 305-316. [Google Scholar] [CrossRef] [PubMed]
[23] Geh, D., Leslie, J., Rumney, R., Reeves, H.L., Bird, T.G. and Mann, D.A. (2022) Neutrophils as Potential Therapeutic Targets in Hepatocellular Carcinoma. Nature Reviews Gastroenterology & Hepatology, 19, 257-273. [Google Scholar] [CrossRef] [PubMed]
[24] Ader, I., Brizuela, L., Bouquerel, P., Malavaud, B. and Cuvillier, O. (2008) Sphingosine Kinase 1: A New Modulator of Hypoxia Inducible Factor 1alpha during Hypoxia in Human Cancer Cells. Cancer Research, 68, 8635-8642. [Google Scholar] [CrossRef